Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-10-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Remuneration and Assessment Committee Work Rules' for Jinling Pharmaceutical Co., Ltd. It details the establishment, composition, responsibilities, decision-making procedures, and meeting rules of the Board's Remuneration and Assessment Committee. The content focuses on governance practices related to board and senior management remuneration and performance evaluation, referencing relevant laws and company bylaws. There are no financial statements, earnings data, or regulatory filings. The document is a governance-related internal rules report rather than a financial report or announcement. Therefore, it fits the category of Governance Information (CGR). The document length is 2431 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2023-10-30 Chinese
《董事会薪酬与考核委员会工作细则》修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing revisions to the "Board of Directors' Remuneration and Assessment Committee Work Rules" of Jinling Pharmaceutical Co., Ltd. It discusses governance structure, committee responsibilities, and procedural changes related to board remuneration and assessment. There is no financial data, earnings information, or regulatory filing announcements. The content focuses on governance practices and internal rules of the company, specifically related to the board's remuneration and assessment committee. Therefore, this document fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-10-30 Chinese
金陵药业关于控股子公司南京鼓楼医院集团宿迁医院有限公司医技楼装饰装修项目的进展公告
Capital/Financing Update Classification · 90% confidence The document is a progress announcement regarding the completion and use of a decoration and renovation project by a controlling subsidiary of the company. It provides details about the project status, references a previous announcement, and discusses the expected impact on business. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no mention of report publication. The document is an operational update related to a capital project but does not discuss financing activities or capital structure changes explicitly. It is not a full financial report or an earnings release. Given the nature of the announcement about project progress and investment implementation, it fits best under Capital/Financing Update (CAP).
2023-10-13 Chinese
金陵药业关于控股子公司业绩承诺补偿涉及诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of litigation related to performance compensation involving its controlling subsidiary. It details court decisions, appeals, and financial implications of the lawsuit. The text includes references to civil judgments, court rulings, and legal fees, indicating it is focused on legal proceedings rather than financial results or management changes. There is no indication that this is a full annual or interim report, earnings release, or other financial report. The document is a legal update on ongoing litigation matters, which fits the category of Legal Proceedings Report (LTR). The document length is 2441 characters, which is typical for an announcement rather than a full report, but the content is substantive about legal proceedings, not just a brief notice or certification. Therefore, the best classification is LTR with high confidence.
2023-10-09 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票募集说明书(申报稿)
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（申报稿）" which translates to "Prospectus (Filing Draft)" for a specific issuance of A shares by Jinling Pharmaceutical Company Limited. It details the issuance method, pricing, number of shares, lock-up periods, use of proceeds, risk factors, and other related information about the capital raising. The document is comprehensive and contains detailed financial and operational information related to the capital raising. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an announcement of a report publication, nor is it an annual or interim report, audit report, or earnings release. It is a detailed document about a specific capital raising event.
2023-09-25 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) for 金陵药业股份有限公司's 2023年度向特定对象发行A股股票 (2023 private placement of A shares). It contains detailed information about the securities issuance, including the sponsor institution, legal and regulatory compliance, underwriting details, shareholder structure, financial data, and the issuance process. The document is a formal sponsorship letter related to a capital raising event through a private placement of shares. It is not a general annual report, earnings release, or management discussion, but specifically a capital/financing update related to a securities issuance. The length (15,000 characters) and detailed content confirm it is the actual issuance sponsorship document, not merely an announcement or a brief notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-09-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.